<unk>  is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer.<unk>  is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution. In July 2009, the U.S. Food and Drug Administration (FDA) approved<unk>  (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab). This was the first genetic test to guide treatment of cancer. In July 2012, the FDA approved a real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.<unk>  is approved for KRAS wild-type metastatic colorectal cancer in the US & Canada (Eli Lilly). In Europe and the rest of the world (Merck KGaA),<unk>  is approved for RAS wild-type metastatic colorectal cancer.
Cetuximab
Necitumumab
Panitumumab
Afatinib
Neratinib
Imatinib
Dasatinib
Lapatinib